We narrowed to 167 results for: Karl Deisseroth

#26969-AAV2

Ready-to-use AAV2 particles produced from pAAV-CaMKIIa-hChR2(H134R)-EYFP (#26969). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(H134R)-EYFP plasmid DNA. CaMKIIa-driven, humanized channelrhodopsin H134R mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Lee et al Nature. 2010 Jun 10. 465(7299):788-92.

Feb. 14, 2018

Academic Institutions and Nonprofits only

#55634-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-mCherry-IRES-Flpo (#55634). In addition to the viral particles, you will also receive purified pAAV-EF1a-mCherry-IRES-Flpo plasmid DNA. EF1a-driven mCherry and bicistronic Flp recombinase expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

May 31, 2019

Academic Institutions and Nonprofits only

#100054-AAV5

Ready-to-use AAV5 particles produced from pAAV.CAG.hChR2(H134R)-mCherry.WPRE.SV40 (#100054). In addition to the viral particles, you will also receive purified pAAV.CAG.hChR2(H134R)-mCherry.WPRE.SV40 plasmid DNA. CAG-driven, humanized channelrhodopsin H134R mutant fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Feb. 15, 2018

Academic Institutions and Nonprofits only

#55639-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-Ef1a-fDIO hChR2(H134R)-EYFP (#55639). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO hChR2(H134R)-EYFP plasmid DNA. Ef1a-driven, Flp-dependent expression of ChR2(H134R)-EYFP. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Feb. 7, 2025

Academic Institutions and Nonprofits only

#20949-AAV9

Ready-to-use AAV9 particles produced from pAAV-double floxed-eNpHR-EYFP-WPRE-pA (#20949). In addition to the viral particles, you will also receive purified pAAV-double floxed-eNpHR-EYFP-WPRE-pA plasmid DNA. EF1a-driven, cre-dependent eNpHR EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

July 12, 2018

Academic Institutions and Nonprofits only

#114470-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-mCherry (#114470). In addition to the viral particles, you will also receive purified pAAV-Ef1a-mCherry plasmid DNA. EF1a-driven mCherry expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Jan. 6, 2022

Academic Institutions and Nonprofits only

#26972-AAV2

Ready-to-use AAV2 particles produced from pAAV-hSyn-eNpHR 3.0-EYFP (#26972). In addition to the viral particles, you will also receive purified pAAV-hSyn-eNpHR 3.0-EYFP plasmid DNA. hSyn-driven eNpHR 3.0-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Aug. 7, 2025

Academic Institutions and Nonprofits only

#114470-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-mCherry (#114470). In addition to the viral particles, you will also receive purified pAAV-Ef1a-mCherry plasmid DNA. EF1a-driven mCherry expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Sept. 15, 2021

Academic Institutions and Nonprofits only

#55641-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-Ef1a-fDIO EYFP (#55641). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO EYFP plasmid DNA. EF1a-driven, Flp-dependent expression of EYFP. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Oct. 21, 2024

Academic Institutions and Nonprofits only

#26975-AAV1

Ready-to-use AAV1 particles produced from pAAV-CaMKIIa-hChR2(H134R)-mCherry (#26975). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(H134R)-mCherry plasmid DNA. CaMKIIa-driven, humanized channelrhodopsin H134R mutant fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Feb. 15, 2018

Academic Institutions and Nonprofits only

#35499-AAV9

Ready-to-use AAV9 particles produced from pAAV-CaMKIIa-C1V1 (t/t)-TS-EYFP (#35499). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-C1V1 (t/t)-TS-EYFP plasmid DNA. CaMKIIa-driven, C1V1 (t/t) fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Yizhar et al Nature. 2011 Jul 27;477(7363):171-8. doi

April 6, 2018

Academic Institutions and Nonprofits only

#26968-AAV5

Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO ChETA-EYFP (#26968). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO ChETA-EYFP plasmid DNA. EF1a-driven, Cre-dependent, ChETA fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gunaydin et al Nat Neurosci. 2010 Mar;13(3):387-92. doi

Feb. 20, 2018

Academic Institutions and Nonprofits only

#105622-AAV1

Ready-to-use AAV1 particles produced from pAAV.CamKII(1.3).eYFP.WPRE.hGH (#105622). In addition to the viral particles, you will also receive purified pAAV.CamKII(1.3).eYFP.WPRE.hGH plasmid DNA. Expression of EYFP from CaMKII(1.3) promoter. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

July 30, 2018

Academic Institutions and Nonprofits only

#114470-AAV5

Ready-to-use AAV5 particles produced from pAAV-Ef1a-mCherry (#114470). In addition to the viral particles, you will also receive purified pAAV-Ef1a-mCherry plasmid DNA. EF1a-driven mCherry expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Sept. 15, 2021

Academic Institutions and Nonprofits only

#55637-AAV2

Ready-to-use AAV2 particles produced from pAAV-EF1a-Flpo (#55637). In addition to the viral particles, you will also receive purified pAAV-EF1a-Flpo plasmid DNA. EF1a-driven Flpo recombinase expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

March 18, 2024

Academic Institutions and Nonprofits only

#177673-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff DREADD Gi-mCherry (#177673). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff DREADD Gi-mCherry plasmid DNA. nEF-driven hM4D(Gi) receptor with an mCherry reporter for CNO-induced neuronal inhibition only in Cre expressing cells and not in Flp expressing cells. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Feb. 16, 2024

Academic Institutions and Nonprofits only

#55645-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hSyn Con/Fon hChR2(H134R)-EYFP (#55645). In addition to the viral particles, you will also receive purified pAAV-hSyn Con/Fon hChR2(H134R)-EYFP plasmid DNA. Synapsin-driven, Cre-dependent and Flp-dependent Channelrhodopsin-EYFP expression for optogenetic activation. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Dec. 5, 2017

Academic Institutions and Nonprofits only

#100050-AAV9

Ready-to-use AAV9 particles produced from pAAV.CaMKIIa.ChETA(E123T/H134R)-eYFP.WPRE.hGH (#100050). In addition to the viral particles, you will also receive purified pAAV.CaMKIIa.ChETA(E123T/H134R)-eYFP.WPRE.hGH plasmid DNA. CaMKIIa-driven, ChETA(E123T/H134R)-eYFP expression for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

April 3, 2018

Academic Institutions and Nonprofits only

#35505-AAV9

Ready-to-use AAV9 particles produced from pAAV-CaMKIIa-hChR2(E123A)-EYFP (#35505). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(E123A)-EYFP plasmid DNA. CaMKIIa-driven hChR2(E123A)-EYFP expression for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Mattis et al Nat Methods. 2011 Dec 18;9(2):159-72. do

May 24, 2018

Academic Institutions and Nonprofits only

#35512-AAV2

Ready-to-use AAV2 particles produced from pAAV-CaMKIIa-hChR2(E123T/T159C)-mCherry (#35512). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(E123T/T159C)-mCherry plasmid DNA. CaMKIIa-driven, humanized channelrhodopsin E123T/T159C mutant fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Mattis et al Nat Methods. 2011 Dec 18;9(2):159-72. do

Nov. 13, 2025

Academic Institutions and Nonprofits only